management rather than addressing acute symptom management (i.e., through intraarticular injections and the use of systemic glucocorticoids). Tofacitinib and ixekizumab were submitted for review and potential approval by the US Food and Drug Administration (FDA) at the time of formulation of this guideline There are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. Thus, health care providers and patients should judge PsA and psoriasis severity on a